Protalix BioTherapeutics Delivers Strong Q3 2025 Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX) recently shared its financial results from the third quarter of 2025 during a conference call held at 8:00 a.m. EST. The biopharmaceutical firm, which specializes in developing and commercializing recombinant therapeutic proteins, provided insights into its financial performance and business progress.
Financial Performance Snapshot
Unveiling Revenue Growth
In the first nine months of 2025, Protalix reported total revenue of $43.6 million, representing a 24% increase compared to the same timeframe in 2024. Despite this growth, the third quarter alone recorded revenues of $17.9 million, which reflects a slight decrease of 1% year-over-year. This temporary dip can be attributed to the varying purchase patterns from partners like Chiesi, Pfizer, and Fiocruz in Brazil, who manage their own inventories actively.
Research and Development Focus
Dror Bashan, President and CEO of Protalix, expressed enthusiasm for their clinical candidate PRX-115, a recombinant PEGylated uricase aimed at treating uncontrolled gout. He pointed out that early human trial results are encouraging, offering hope for this therapy to stand out in the market with its long-acting profile that could enhance patient compliance. Plans are underway to initiate a phase 2 clinical trial for PRX-115.
Recent Company Developments
Regulatory Updates
In October 2025, Protalix submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration regarding their planned phase 2 trial for PRX-115. The application has since become effective following the standard review. Additionally, the company is collaborating with Chiesi Global Rare Diseases to hold ongoing discussions about regulatory feedback concerning the dosing regimen of Elfabrio, their product approved in 2023.
Financial Highlights from Q3
For the third quarter of 2025, Protalix recorded $17.7 million in goods sold, indicating a minor decline from the previous year's figures. This breakdown included $8.8 million in Elfabrio sales, $2.8 million from Elelyso to Pfizer, and $6.1 million in sales to Fiocruz.
Looking Ahead: Strategies and Expectations
Investment in R&D
Protalix’s commitment to research and development remains strong, with R&D expenses totaling approximately $4.5 million in Q3 2025. This increase of 50% from 2024's expenditure reflects the preparations necessary for advanced clinical trials of PRX-115. The company expects the trend of increased investment in R&D to persist as they pursue additional clinical and preclinical programs.
Addressing Financial Position
As of September 30, 2025, Protalix held $29.4 million in cash and cash equivalents as well as short-term bank deposits, sufficient to support its capital needs for the next year. Their financial strategy will focus on sustaining this position while advancing product development and commercial initiatives.
Investor and Company Engagement
Engaging with Stakeholders
To keep its investors updated, Protalix will continue hosting conference calls and webcasts, allowing stakeholders to engage directly with management about company performance and future plans. The recent call included detailed reports on financial results and product advancements, reinforcing its commitment to transparency.
Frequently Asked Questions
What are Protalix's revenue results for Q3 2025?
Protalix reported total revenues of $17.9 million for the third quarter, which marks a 1% decrease compared to the same period in 2024.
What is PRX-115 developed by Protalix?
PRX-115 is a candidate for treating uncontrolled gout, currently progressing to phase 2 clinical trials after promising early results.
How much did Protalix invest in research and development in Q3 2025?
The research and development expenses for Q3 2025 were approximately $4.5 million, representing a 50% increase compared to the previous year.
What is Protalix's current cash position?
As of the end of the third quarter, Protalix had $29.4 million in cash and cash equivalents, which is expected to sustain its operations and initiatives for at least the next 12 months.
How does Protalix plan to engage with investors?
Protalix will continue its practice of hosting conference calls and webcasts, keeping stakeholders informed about financial performance and strategic directions.
